This article is freely available to all

Article Abstract

Because this does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: I thank Drs. Carroll and Lee for their excellent comments1 and for providing additional viewpoints through which to analyze the case reports and subtype neuroleptic malignant syndrome (NMS). They have clearly described the additional risk factors for NMS to be considered. As we focused on NMS only and the cases reviewed were already diagnosed as NMS, we did not go into the details of differential diagnosis.’ ‹